Here, you can register for the Sepsis Alliance AMR Conference recordings in one package. If you would like to review individual sessions, you can do so here.
This session was part of the Sepsis Alliance AMR Conference 2023.
Sustainable resources are needed to improve antibiotic stewardship in healthcare facilities across the country. Healthcare professionals and networks can solve gaps that worsen known health inequities in antibiotic prescribing and use by implementing data-driven solutions, sharing knowledge, and integrating resources. This keynote session will discuss current policy efforts that aim to improve antibiotic stewardship practices and economic incentive policies.
Learning Objectives:
At the end of the session, the learner should be able to:
Understand how both improving the development pipeline for new antibiotics and ensuring optimal use of existing ones are integral to combatting antimicrobial resistance;
Discuss how policies can help spur the adoption of antibiotic stewardship practices across healthcare settings;
Describe how economic incentive policies aim to help revitalize the antibiotic pipeline.
Target Audience:
Nurses, advanced practice providers, physicians, emergency responders, pharmacists, medical technologists, respiratory therapists, physical/occupational therapists, infection prevention specialists, data/quality specialists, and more.
David Hyun, MD
Project Director of the Antibiotic Resistance Project
The Pew Charitable Trusts
David Hyun, MD, directs Pew’s antibiotic resistance project, which supports policies that remove regulatory, economic, and scientific obstacles to the discovery of new antibiotics and ensures that antibiotics are prescribed only when necessary.
Before joining Pew, he practiced medicine at Children’s National Medical Center, where he developed and co-chaired the antibiotic stewardship program. He also was an assistant professor of pediatrics at George Washington University School of Medicine. Dr. Hyun has published and lectured widely on managing antibiotic use in inpatient and outpatient settings.
Dr. Hyun received a bachelor’s degree in chemistry from the University of Minnesota and a Doctor of Medicine from Ohio State University’s College of Medicine. He completed his residency in pediatrics at Indiana University and a fellowship program in pediatric infectious disease at Baylor College of Medicine.
Provider approved by the California Board of Registered Nursing, Provider Number CEP17068 for 1.0 contact hours.
Other healthcare professionals will receive a certificate of attendance for 0.75 contact hours.
Medical Disclaimer
The information on or available through this site is intended for educational purposes only. Sepsis Alliance does not represent or guarantee that information on or available through this site is applicable to any specific patient’s care or treatment. The educational content on or available through this site does not constitute medical advice from a physician and is not to be used as a substitute for treatment or advice from a practicing physician or other healthcare professional. Sepsis Alliance recommends users consult their physician or healthcare professional regarding any questions about whether the information on or available through this site might apply to their individual treatment or care.
This session was part of the Sepsis Alliance AMR Conference 2023.
This session will cover two important CDC initiatives that are designed to combat AMR and sepsis respectively. Participants will gain a comprehensive understanding of the implementation, uptake, and future direction of the Core Elements of Hospital Antibiotic Stewardship Programs. Additionally, participants will be introduced to the forthcoming CDC Core Elements of Hospital Sepsis Programs, including a preview of the program’s scope and purpose.
Learning Objectives:
At the end of the session, the learner should be able to:
Discuss Core Elements of Hospital Antibiotic Stewardship Programs implementation, uptake, and future direction;
Describe the scope and purpose of the upcoming CDC Core Elements of Hospital Sepsis Programs;
Preview components of the Sepsis Core Elements.
Target Audience:
Nurses, advanced practice providers, physicians, emergency responders, pharmacists, medical technologists, respiratory therapists, physical/occupational therapists, infection prevention specialists, data/quality specialists, and more.
Melinda Neuhauser, PharmD, MPH
Pharmacist and Acute Care Lead
Office of Antibiotic Stewardship, Division of Healthcare Quality Promotion, Centers for Disease Control and Prevention (CDC)
Melinda Neuhauser, PharmD, MPH, FCCP, FASHP, FIDP is pharmacist and Acute Care Lead for Centers for Disease Control and Prevention (CDC) Office of Antibiotic Stewardship in the Division of Healthcare Quality Promotion. Dr. Neuhauser earned a Doctor of Pharmacy from the University of Minnesota College of Pharmacy and a Master in Public Health from Johns Hopkins Bloomberg School of Public Health. She also completed an infectious diseases residency at Detroit Receiving Hospital and infectious diseases fellowship at University of Illinois at Chicago.
Raymund Dantes, MD, MPH
Associate Professor of Medicine
Emory University School of Medicine
Raymund Dantes, MD, MPH, is an Associate Professor of Medicine at the Emory University School of Medicine, where he practices hospital medicine. He is also on the Sepsis Leadership Committee for Emory Healthcare. Dr. Dantes works on many sepsis-related activities for the CDC, and serves as a medical advisor to the CDC's National Healthcare Safety Network, where he leads research and development efforts of new healthcare quality measures in the pipeline.
Provider approved by the California Board of Registered Nursing, Provider Number CEP17068 for 0.7 contact hours.
Other healthcare professionals will receive a certificate of attendance for 0.5 contact hours.
Medical Disclaimer
The information on or available through this site is intended for educational purposes only. Sepsis Alliance does not represent or guarantee that information on or available through this site is applicable to any specific patient’s care or treatment. The educational content on or available through this site does not constitute medical advice from a physician and is not to be used as a substitute for treatment or advice from a practicing physician or other healthcare professional. Sepsis Alliance recommends users consult their physician or healthcare professional regarding any questions about whether the information on or available through this site might apply to their individual treatment or care.
This session was part of the Sepsis Alliance AMR Conference 2023.
Artificial intelligence (AI) has been increasingly applied in medicine and, in particular, in the development of new drugs to combat antimicrobial resistance (AMR). AI can serve as a new tool to shorten drug development time and costs in the development of new therapeutics and antibiotics. During this session, the presenter will discuss the use of AI to combat AMR and other infections that can lead to sepsis and the importance of the accelerated development of new drugs.
Learning Objectives:
At the end of the session, the learner should be able to:
Summarize the basics of AI and other forms of computing;
List the ways in which AI can be leveraged to combat AMR;
Identify how AI can be used to drastically reduce the time and cost to discover new drugs.
Target Audience:
Nurses, advanced practice providers, physicians, emergency responders, pharmacists, medical technologists, respiratory therapists, physical/occupational therapists, infection prevention specialists, data/quality specialists, and more.
Apart from Drug Discovery, Professor Mukhopadhyay has worked on AI for environmental challenges, education, port and supply chain security, satellite image understanding, video and image analytics, design of intelligent buildings and transportation systems, wildfire prediction and detection, conservation of endangered species and intelligent cyber-physical-human systems, to name a few. His DeepSat framework for satellite imagery understanding forms the basis of NASA Earth Exchange (NEX) (see DeepSAT: A Deep Learning Approach to Tree-Cover Delineation in 1-m NAIP Imagery for the Continental United States - NASA Technical Reports Server (NTRS)).
In the last 13 years, Professor Mukhopadhyay has received more than $9 million in research grants. His research has been funded by the NSF, DARPA, ARO, ONR, NGA, NASA, DOE, USDOT, USDA, NRL, state agencies, and private industry. Professor Mukhopadhyay has published around 125 refereed publications in reputed journals and conferences. He has been awarded 3 US Patents and has 8 US patents pending. Additionally, he has received numerous awards for his research and cofounded a startup, Ailectric, for commercializing his research on sound, video, and image analytics (Ailectric | Home | Artificial Intelligence | Deep Learning). He serves as an associate editor for IEEE Transactions on Artificial Intelligence and Remote Sensing letters and has served in the program committees of AAAI.
Provider approved by the California Board of Registered Nursing, Provider Number CEP17068 for 0.8 contact hours.
Other healthcare professionals will receive a certificate of attendance for 0.5 contact hours.
Medical Disclaimer
The information on or available through this site is intended for educational purposes only. Sepsis Alliance does not represent or guarantee that information on or available through this site is applicable to any specific patient’s care or treatment. The educational content on or available through this site does not constitute medical advice from a physician and is not to be used as a substitute for treatment or advice from a practicing physician or other healthcare professional. Sepsis Alliance recommends users consult their physician or healthcare professional regarding any questions about whether the information on or available through this site might apply to their individual treatment or care.
This session was part of the Sepsis Alliance AMR Conference 2023.
Antimicrobial Resistance (AMR) is a complex issue that needs to be tackled with a systems thinking approach, and interdisciplinary collaboration is key. The One Health Approach establishes that the health of humans, domestic and wild animals, plants, and the wider environment (including ecosystems) are closely linked and inter-dependent. Therefore, AMR should be addressed with a One Health approach in mind.
Animal health can broadly be divided into two sectors. The first sector is animal agriculture where a population medicine approach is used to address animal health issues, and where the main objective is to provide nutritious and healthy safe animal protein for the consumers.
In this session, attendees will gain an understanding of the veterinary perspective on ‘One Health’ system thinking, as well as learn about the current challenges and opportunities for antimicrobial stewardship in animal health, and how that ultimately affects the lives of humans.
Learning Objectives:
At the end of the session, the learner should be able to:
Understand One Health from the veterinary perspective;
Review the challenges around antibiotic use in animal health;
Describe opportunities for antimicrobial stewardship in animal health.
Target Audience:
Nurses, advanced practice providers, physicians, emergency responders, pharmacists, medical technologists, respiratory therapists, physical/occupational therapists, infection prevention specialists, data/quality specialists, and more.
Lucas Pantaleon DVM, MBA
Veterinary Industry Advisor
DVM One Health
Lucas Pantaleon, DVM, MBA, is a veterinarian and Board-Certified Large Animal Internal Medicine Specialist. He also holds an MBA and is the founder of DVM One Health. He works with companies and individuals to implement strategies to improve animal health by focusing on antibiotic use, infection prevention, One Health, and Value-Based veterinary care concepts in different sectors of animal health. Dr. Pantaleon also practices small animal general medicine. He is involved in different committees, councils, and Boards, working to better the health of pets and livestock. He enjoys researching, advising, teaching, speaking, and writing about infection prevention, AMR, and One Health for varied sectors within the veterinary industry and beyond. He lives in Kentucky with his wife and twin daughters.
Provider approved by the California Board of Registered Nursing, Provider Number CEP17068 for 1.0 contact hours.
Other healthcare professionals will receive a certificate of attendance for 0.75 contact hours.
Medical Disclaimer
The information on or available through this site is intended for educational purposes only. Sepsis Alliance does not represent or guarantee that information on or available through this site is applicable to any specific patient’s care or treatment. The educational content on or available through this site does not constitute medical advice from a physician and is not to be used as a substitute for treatment or advice from a practicing physician or other healthcare professional. Sepsis Alliance recommends users consult their physician or healthcare professional regarding any questions about whether the information on or available through this site might apply to their individual treatment or care.
This session was part of the Sepsis Alliance AMR Conference 2023.
Much of the focus of Antimicrobial Stewardship programs has been on optimizing use of antibiotics in bacterial infections. However, with the rising rates of antifungal resistance, antifungal stewardship is also necessary. Unlike antibacterial drugs, there are only a limited number of drugs available to treat invasive fungal infections. In this session, the audience will learn about the current epidemiology of antifungal resistance worldwide, the current limitations of antifungal therapy, the effects of COVID-19 pneumonia on the risk of fungal infections, and what antifungal stewardship steps could limit the rise of antifungal resistance.
Learning Objectives:
At the end of the session, the learner should be able to:
Discuss the epidemiology of antifungal resistance and how it affects human health;
Identify the main drivers for the increasing trend in antifungal resistance;
Describe preventative measures to curb the development of antifungal resistance.
Target Audience:
Nurses, advanced practice providers, physicians, emergency responders, pharmacists, medical technologists, respiratory therapists, physical/occupational therapists, infection prevention specialists, data/quality specialists, and more.
Emi Minejima, PharmD
Associate Professor of Clinical Pharmacy
USC School of Pharmacy
Dr. Minejima received her PharmD degree from University of California, San Diego Skaggs School of Pharmacy in 2005 and completed both her residency training in pharmacy practice and infectious diseases pharmacotherapy at Huntington Hospital in Pasadena, CA. After residency, she joined the faculty at the University of Southern California, School of Pharmacy where she is currently an Associate Professor of Clinical Pharmacy. Her clinical practice is based at Los Angeles County/USC Medical Center where she helps run the antimicrobial stewardship program and is the director for PGY2 infectious diseases residency program. Her research interests include S. aureus infections and optimizing the use of antibiotics to improve care for the medically underserved population.
Provider approved by the California Board of Registered Nursing, Provider Number CEP17068 for 1.0 contact hours.
Other healthcare professionals will receive a certificate of attendance for 0.75 contact hours.
Medical Disclaimer
The information on or available through this site is intended for educational purposes only. Sepsis Alliance does not represent or guarantee that information on or available through this site is applicable to any specific patient’s care or treatment. The educational content on or available through this site does not constitute medical advice from a physician and is not to be used as a substitute for treatment or advice from a practicing physician or other healthcare professional. Sepsis Alliance recommends users consult their physician or healthcare professional regarding any questions about whether the information on or available through this site might apply to their individual treatment or care.
This session was part of the Sepsis Alliance AMR Conference 2023.
Antimicrobial stewardship is an important strategy to address the public health crisis of antimicrobial resistance. The emergence of telemedicine's use in a variety of innovative ways, especially during the COVID-19 pandemic, has allowed for antimicrobial stewardship programs to be implemented in settings with limited resources. In this session, the presenter will discuss the role of antimicrobial stewardship and its impact on antimicrobial resistance. Additionally, the presenter will provide a better understanding of telemedicine’s impact on antimicrobial usage.
Learning Objectives:
At the end of the session, the learner should be able to:
Describe the role of antimicrobial stewardship on the impact of AMR;
Understand the role of telemedicine on antimicrobial usage.
Target Audience:
Nurses, advanced practice providers, physicians, emergency responders, pharmacists, medical technologists, respiratory therapists, physical/occupational therapists, infection prevention specialists, data/quality specialists, and more.
Thomas M. File, Jr., MD, MSc, MACP, FIDSA, FCCP
Chair of the Infectious Disease Division and Co-Director of Antimicrobial Stewardship
Summa Health
Thomas File, MD, MSc, MACP, FIDSA, FCCP, is Chair of the Infectious Disease Division and Co-Director of Antimicrobial Stewardship at Summa Health in Akron, Ohio. He is also a professor of Internal Medicine, Master Teacher, and Chair of the Infectious Disease Section at Northeast Ohio Medical University. After graduating from medical school at the University of Michigan, Ann Arbor, Dr. File received his Master of Science in medical microbiology from Ohio State University in Columbus, where he also completed his fellowship in infectious diseases.
Dr. File is a past President of the Board of Directors of the Infectious Diseases Society of America (IDSA) and Past President of the National Foundation for Infectious Diseases (NFID). He is a Master of the American College of Physicians, a fellow of the American College of Chest Physicians, and a member of the American Thoracic Society. He is also a past Chairperson of the Standards and Practice Guidelines Committee of the IDSA and served as a member of several guideline panels. Additionally, he is a past-president of the Infectious Disease Society of Ohio.
Dr. File’s primary research interests include respiratory tract infections, antimicrobial stewardship, immunizations in adults, and evaluation of new antimicrobial agents. A frequent lecturer, nationally and internationally, he has published more than 250 articles, abstracts, and textbook chapters, focusing on the diagnosis, etiology, and treatment of infectious diseases, especially on respiratory tract infections and antimicrobial stewardship. He received the Watanakunakorn Clinician Award from the IDSA in 2013 and the John P Utz Leadership award from NFID in 2017. He authors sections on community-acquired pneumonia, acute bronchitis, and hospital-acquired pneumonia in UpToDate. Dr. File is currently Editor-in-Chief of Infectious Diseases in Clinical Practice.
Provider approved by the California Board of Registered Nursing, Provider Number CEP17068 for 1.0 contact hours.
Other healthcare professionals will receive a certificate of attendance for 0.75 contact hours.
Medical Disclaimer
The information on or available through this site is intended for educational purposes only. Sepsis Alliance does not represent or guarantee that information on or available through this site is applicable to any specific patient’s care or treatment. The educational content on or available through this site does not constitute medical advice from a physician and is not to be used as a substitute for treatment or advice from a practicing physician or other healthcare professional. Sepsis Alliance recommends users consult their physician or healthcare professional regarding any questions about whether the information on or available through this site might apply to their individual treatment or care.
Sponsored session, part of Sepsis Alliance AMR Conference 2023
Description:
This bioMérieux sponsored session was part of the Sepsis Alliance AMR Conference 2023.
The rapid growth of antibiotic resistant bacteria makes it difficult to treat infections, which can lead to sepsis. However, with optimized sepsis management protocols and guidance from antimicrobial stewardship programs, it is possible to combat antimicrobial resistance alongside sepsis. In this sponsored session, participants will learn why antimicrobial stewardship is an integral part of a sepsis protocol. The presenter will explain how to optimize sepsis care and improve antimicrobial use, keeping the patient as the primary focus and ensuring the use of the right drug at the right time.
Target Audience:
Nurses, advanced practice providers, physicians, emergency responders, pharmacists, medical technologists, respiratory therapists, physical/occupational therapists, infection prevention specialists, data/quality specialists, and more.
Session Supporter:
Sepsis Alliance gratefully acknowledges the support of this session provided by bioMérieux.
Katherine Perez, PharmD, BCPS
Director of Antimicrobial Stewardship
bioMérieux
Katherine Perez, PharmD, BCPS, is a patient care-oriented antimicrobial stewardship pharmacist dedicated to executing high-quality interventions and demonstrating impact on clinical and economic outcomes. She has a Doctor of Pharmacy degree from the University of Texas College of Pharmacy in Austin, Texas. Dr. Perez completed a postdoctoral pharmacy practice residency in a combined program at UHS Hospital and the Pharmacotherapy Education and Research Center at the UT Health Science Center in San Antonio, Texas followed by a specialty residency in infectious diseases pharmacotherapy at Houston Methodist Hospital, Houston, Texas. She is board certified in infectious diseases pharmacotherapy by the Board of Pharmaceutical Specialties
Sponsored session, part of Sepsis Alliance AMR Conference 2023
Description:
This Recce Pharmaceuticals sponsored session was part of the Sepsis Alliance AMR Conference 2023.
Recce Pharmaceuticals Ltd (ASX: RCE, FSE: R9Q) is pioneering the development and commercialization of a New Class of Synthetic Anti-Infectives designed to address the urgent global health threat posed by antibiotic-resistant superbugs and emerging viral pathogens. With no new class of antibiotics in over 30 years, a novel class of medication that can tackle multidrug-resistant bacteria and does not increase antibiotic resistance is essential to tackle the constant infective threat. In this sponsored session, learn about Recce’s synthetic anti-infective compound, RECCE® 327 (R327), which has demonstrated bactericidal activity against all six ESKAPE pathogens without contributing to resistance. With a unique mechanism of action, the compound has the ability to continuously kill multidrug-resistant superbugs.
Target Audience:
Nurses, advanced practice providers, physicians, emergency responders, pharmacists, medical technologists, respiratory therapists, physical/occupational therapists, infection prevention specialists, data/quality specialists, and more.
Session Supporter:
Sepsis Alliance gratefully acknowledges the support of this session provided by Recce Pharmaceuticals.
James Graham
Managing Director & Chief Executive Officer
Recce Pharmaceuticals
James Graham is the Chief Executive Officer of Recce Pharmaceuticals. He was formerly the Executive Director and has extensive experience in marketing, business development, and commercialization of early-stage technologies with global potential. Mr. Graham has served on Recce’s Board of Directors for six years and has invested in almost every capital raise to date with a focus on expanding Recce’s commercial opportunities and clinical initiatives.
Sponsored session, part of Sepsis Alliance AMR Conference 2023
Description:
This Thermo Fisher sponsored session was part of the Sepsis Alliance AMR Conference 2023.
B·R·A·H·M·S PCT is an invaluable marker to help assess presence or absence of a bacterial infection and can be used as an aid in antibiotic therapy for patients with suspected or confirmed lower respiratory tract infection (LRTI). This sponsored session reviews the utility of procalcitonin (PCT) testing to aid initiation and discontinuation of antibiotics for patients with clinical presentation of bacterial infection. Join Dr. Mike Broyles as he discusses the ways B·R·A·H·M·S PCT supports the responsible use of antibiotics to prolong their effectiveness.
Target Audience:
Nurses, advanced practice providers, physicians, emergency responders, pharmacists, medical technologists, respiratory therapists, physical/occupational therapists, infection prevention specialists, data/quality specialists, and more.
Session Supporter:
Sepsis Alliance gratefully acknowledges the support of this session provided by Thermo Fisher.
Michael Broyles, PharmD
Director of Medical Affairs, Biomarkers
ThermoFisher Scientific
Mike Broyles, PharmD has more than 30 years of experience as a Hospital Pharmacy and Laboratory Director providing patients with current concepts in the clinical use of drugs with a focus on antimicrobial stewardship. His current role is Director of Medical Affairs, Biomarkers for Thermo Fisher Scientific. Prior to joining Thermo Fisher Scientific, Mike had more than 25 years consulting for a large IHN as their pharmacy advisory chairman to develop and implement clinical initiatives. His goal is to provide the leading thought processes in patient management and use technology to enhance the ability of clinicians to have the best options in patient’s clinical status, decision support, and improving outcomes through better clinical care.
Sponsored session, part of Sepsis Alliance AMR Conference 2023
Description:
This Bluejay Diagnostics sponsored session was part of the Sepsis Alliance AMR Conference 2023.
This session will discuss the challenges of identifying serious complication risks and treating patients with high-risk conditions including severe COVID-19, sepsis, and respiratory failure in emergency departments and intensive care unit settings. The presenter will also discuss Bluejay's Symphony IL-6 test, which has the potential to provide simple, reliable, rapid, near-patient testing by delivering quantitative measurements of IL-6 to determine the need for additional patient care, acute intervention, and monitoring.
Target Audience:
Nurses, advanced practice providers, physicians, emergency responders, pharmacists, medical technologists, respiratory therapists, physical/occupational therapists, infection prevention specialists, data/quality specialists, and more.
Session Supporter:
Sepsis Alliance gratefully acknowledges the support of this session provided by Bluejay Diagnostics.
Mark Feinberg, MD
Associate Professor of Medicine
Harvard Medical School
Mark W. Feinberg, MD, is a cardiologist and vascular biologist at Brigham and Women’s Hospital (BWH) and an Associate Professor of Medicine at Harvard Medical School, Boston. Dr. Feinberg is Director, Program in Cardiovascular RNA Biology Research that investigates inflammatory mechanisms leading to the development of a range of macrovascular (e.g. atherosclerosis, coronary, and peripheral artery disease) and microvascular disease states (e.g. diabetes). His group has discovered non-coding RNAs and cardiovascular biomarkers, and has translated these findings into novel therapeutic approaches for ischemic cardiovascular disease. Dr. Feinberg has held various leadership roles in cardiovascular research including his service on international and national peer review study sections, editorial service, and as a Co-Chair of the Brigham Research Institute’s Cardiovascular, Diabetes, and Metabolic Disorders Center. Dr. Feinberg completed his Cardiovascular Medicine fellowship training at Brigham and Women’s Hospital, where he subsequently joined the faculty. Dr. Feinberg was inducted as a member of the American Society of Clinical Investigation and has received several major research awards including an American Heart Association Louis N. and Arnold M. Katz Prize Finalist and the David W. Haack Memorial Award.
Jason Cook, PhD
Chief Technology Officer
Bluejay Diagnostics
Prior to joining Bluejay Diagnostics in 2021, Jason Cook, PhD, served as Chief Executive Officer at NanoHybrids, Inc., a nanotechnology company focused on developing theranostic nanoparticle platform technologies. He was Director and Chairman of the Board from 2020–21, and Senior Scientist from 2014–17, overseeing the development of several core technologies. Dr. Cook received his PhD in Biomedical Engineering from The University of Texas at Austin, focusing on the design and development of medical diagnostic systems. His postdoctoral work included improving the bioconjugation strategies of nanoparticles for molecular targeting. Dr. Cook also serves as ad-hoc Reviewer for numerous panels at the National Institute of Health and peer-reviewed scientific journals.
Recorded On: 04/27/2023
Recorded On: 04/26/2023
Recorded On: 04/26/2023
Recorded On: 04/26/2023
Recorded On: 04/26/2023
Recorded On: 04/26/2023
Recorded On: 04/26/2023
Recorded On: 04/26/2023
Recorded On: 04/26/2023
Recorded On: 04/26/2023
